Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Françoise Rothé

Showing results (11-20 of 61) with videos related to

Pageof 7
Sort By:
Frontiers in Oncology|August 20, 2021
Circulating Tumor DNA to Interrogate the Safety of Letrozole-Associated Controlled Ovarian Stimulation for Fertility Preservation in Breast Cancer PatientsFrançoise Rothé, Matteo Lambertini, Oranite Goldrat, et al.
NPJ Breast Cancer|July 5, 2022
Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysisFrançoise Rothé, David Venet, Dieter Peeters, et al.
Journal of the National Cancer Institute|October 31, 2019
Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment ApproachYacine Bareche, Laurence Buisseret, Tina Gruosso, et al.
NPJ Breast Cancer|August 16, 2018
Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutationsBastien Nguyen, David Venet, Hatem A Azim, et al.
Plos One|July 9, 2011
Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancerFrançoise Rothé, Michail Ignatiadis, Carole Chaboteaux, et al.
BMC Cancer|April 5, 2019
CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trialFrançoise Rothé, Marion Maetens, Ghizlane Rouas, et al.
European Journal of Immunology|May 2, 2009
Human natural Treg microRNA signature: role of microRNA-31 and microRNA-21 in FOXP3 expressionRedouane Rouas, Hussein Fayyad-Kazan, Nabil El Zein, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 4, 2026
Spatial transcriptomics reveals tumor microenvironment-driven subtypes of invasive lobular carcinomaMatteo Serra, Mattia Rediti, Laetitia Collet, et al.
Oncotarget|September 12, 2015
Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trialAmir Sonnenblick, Sylvain Brohée, Debora Fumagalli, et al.
BMC Genomics|November 22, 2014
Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technologyDebora Fumagalli, Alexis Blanchet-Cohen, David Brown, et al.
Pageof 7

Showing results (11-20 of 61) with videos related to

Sort By:
Pageof 7
Frontiers in Oncology|August 20, 2021
Circulating Tumor DNA to Interrogate the Safety of Letrozole-Associated Controlled Ovarian Stimulation for Fertility Preservation in Breast Cancer PatientsFrançoise Rothé, Matteo Lambertini, Oranite Goldrat, et al.
NPJ Breast Cancer|July 5, 2022
Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysisFrançoise Rothé, David Venet, Dieter Peeters, et al.
Journal of the National Cancer Institute|October 31, 2019
Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment ApproachYacine Bareche, Laurence Buisseret, Tina Gruosso, et al.
NPJ Breast Cancer|August 16, 2018
Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutationsBastien Nguyen, David Venet, Hatem A Azim, et al.
Plos One|July 9, 2011
Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancerFrançoise Rothé, Michail Ignatiadis, Carole Chaboteaux, et al.
BMC Cancer|April 5, 2019
CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trialFrançoise Rothé, Marion Maetens, Ghizlane Rouas, et al.
European Journal of Immunology|May 2, 2009
Human natural Treg microRNA signature: role of microRNA-31 and microRNA-21 in FOXP3 expressionRedouane Rouas, Hussein Fayyad-Kazan, Nabil El Zein, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 4, 2026
Spatial transcriptomics reveals tumor microenvironment-driven subtypes of invasive lobular carcinomaMatteo Serra, Mattia Rediti, Laetitia Collet, et al.
Oncotarget|September 12, 2015
Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trialAmir Sonnenblick, Sylvain Brohée, Debora Fumagalli, et al.
BMC Genomics|November 22, 2014
Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technologyDebora Fumagalli, Alexis Blanchet-Cohen, David Brown, et al.
Pageof 7